HPTN083: A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir . . . A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), for Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men

Study Location:

Baltimore

Topic:

HIVHIV Prevention

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/NCT02720094?term=HPTN083&rank=1

Coordinator:

Ilene Wiggins

Enrollment:

Open

Trial Period:

Ongoing

HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected men and transgender women who have sex with men (MSM and TGW).

HPTN 083 will enroll approximately 4500 HIV-uninfected MSM and TGW at risk for acquiring HIV infection, ages 18 or older at sites in the Americas, Asia and South Africa.

Categories

Location
Topic

Clinical Trials

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More

A5354/EARLIER: Effect of Antiretroviral Treatment Initiated...

This study will include people who have very recently been infected with HIV and will start anti-HIV (antiretroviral) drugs...

Read More

A5308: A Prospective, Single-Arm, Open-Label Study to...

This study is being done with people who are infected with HIV, but do not show any signs of having HIV. They are also feeling...

Read More

A5314: Effect of LDMTX on Inflammation in HIV-infected...

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

Read More

NWCS 445: Novel Biomarkers to Shorten TB Treatment

Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...

Read More